SELLAS Life Sciences Group (NASDAQ:SLS) Announces Earnings Results, Misses Estimates By $0.01 EPS

SELLAS Life Sciences Group (NASDAQ:SLS) announced its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01), FiscalAI reports.

SELLAS Life Sciences Group Stock Up 0.1%

NASDAQ:SLS traded up $0.01 during midday trading on Tuesday, hitting $11.05. The stock had a trading volume of 4,565,608 shares, compared to its average volume of 8,285,710. SELLAS Life Sciences Group has a one year low of $1.39 and a one year high of $15.88. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of -48.04 and a beta of 2.48. The stock has a 50-day moving average of $10.95 and a 200 day moving average of $7.19.

Analyst Upgrades and Downgrades

SLS has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Monday, July 6th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, SELLAS Life Sciences Group presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several hedge funds have recently made changes to their positions in the company. Beacon Pointe Advisors LLC bought a new position in shares of SELLAS Life Sciences Group during the 4th quarter worth $38,000. Stifel Financial Corp purchased a new stake in SELLAS Life Sciences Group in the fourth quarter worth about $49,000. Boothbay Fund Management LLC purchased a new stake in SELLAS Life Sciences Group in the fourth quarter worth about $52,000. BNP Paribas Financial Markets grew its holdings in SELLAS Life Sciences Group by 89.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after acquiring an additional 9,299 shares in the last quarter. Finally, Great Valley Advisor Group Inc. purchased a new position in SELLAS Life Sciences Group during the 2nd quarter valued at about $44,000. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.